Australia has an increasing demand for specialist contract formulation and manufacturing facilities to provide bespoke pharmaceutical products that meet regulatory and quality control standards.
The project will establish a unique and specialist manufacturing and training facility, Ab-initio, that provides cost effective manufacturing solutions for small-medium-enterprises (SMEs), academics, clinicians and larger pharma for early phase clinical trials in Australia. The consortium members hope that this project will assist Australia’s position as a global leader in the pharmaceutical sector.
Outcomes: Facility has been built and is waiting for the final equipment and hand-over. Nine staff have been employed. The facility will progress TGA certification once complete.
|State||New South Wales|
|Consortium Lead||The University of Sydney|
|Consortium Members||Ab Initio Pharma, Sydney Local Health District (SLHD) & ARCS Australia|
|State Government Contribution||$200,000|
|Project Duration||July 2018 - October 2021 (Finished)|
|Contact||Paul Young, Ab Initio - firstname.lastname@example.org|